Regeneron Pharmaceuticals Inc. (REGN)

597.00
NASDAQ : Health Technology
Prev Close 598.54
Day Low/High 578.43 / 600.14
52 Wk Low/High 271.37 / 618.71
Avg Volume 1.56M
Exchange NASDAQ
Shares Outstanding 110.67M
Market Cap 67.99B
EPS 19.40
P/E Ratio 30.08
Div & Yield N.A. (N.A)
Ophthtech Shares Plunge as Drug Fails in Late Stage Trial

Ophthtech Shares Plunge as Drug Fails in Late Stage Trial

A drug made by Ophthotech failed in a late stage trial, sending shares of the stock plunging.

Cramer: With Trump, Everything's a Negotiation

Cramer: With Trump, Everything's a Negotiation

Just ask the drug companies or Boeing.

Cramer: We Are in Stage 2 of the Trump Love Affair With Business

Cramer: We Are in Stage 2 of the Trump Love Affair With Business

Hillary isn't the only one who seems to favor workers over capital. Trump does, too.

Takeover Talk Surrounds Biotech Firm Alexion, Says Jim Cramer

Takeover Talk Surrounds Biotech Firm Alexion, Says Jim Cramer

Jim Cramer explains the recent moves in biotechs and comments on reports regarding a Justice Department investigation into generic drug makers.

Markets Await October Jobs Report Friday

Markets Await October Jobs Report Friday

The October jobs report is released on Friday, November 4th at 8:30 a.m. Eastern.

Closing Bell: Regeneron Slides on FDA Ruling; FBI Reopens Clinton Case

Closing Bell: Regeneron Slides on FDA Ruling; FBI Reopens Clinton Case

It was a volatile end to the week after federal investigators reopened a case into Hillary Clinton's email server.

FDA Puts Hold on Regeneron Pain-Drug Study

FDA Puts Hold on Regeneron Pain-Drug Study

Shares of Regeneron Pharmaceuticals were lower Monday after The Food and Drug Administration put a drug study on hold.

Cramer: Sing It, Martha -- Nowhere to Run to in This Market, Nowhere to Hide

Cramer: Sing It, Martha -- Nowhere to Run to in This Market, Nowhere to Hide

On days like this, the money just keeps sloshing around.

Pfizer's Deal to Buy Medivation May Give the Company Its Groove Back

Pfizer's Deal to Buy Medivation May Give the Company Its Groove Back

Pfizer's $14 billion acquisition of Medivation is a strong purchase, according to Jim Cramer, who now wonders what Sanofi will do next.

Cramer: Here's What to Embrace and What to Shun

Cramer: Here's What to Embrace and What to Shun

With enough of earnings season now under our belt, we check out the promising themes and the sectors to avoid.

Amgen and Regeneron Expanding Anti-Cancer Research

Amgen and Regeneron Expanding Anti-Cancer Research

The two Big Pharma giants are looking for new ways to drive growth through anti-cancer treatments.

Cramer: What Are You Thinking? It Should Be Long Term

Cramer: What Are You Thinking? It Should Be Long Term

That may be the best way to get through the notorious month of August.

Jim Cramer: I’m Looking at the Biotechs

Jim Cramer: I’m Looking at the Biotechs

Utilities and other high yielding sectors are reaching overbought levels, so investors may want to rotate into biotechs, says Jim Cramer.

Regeneron Is Regenerating Lost Profits

Regeneron Is Regenerating Lost Profits

Investors should risk below $380 for now.

Cramer: Might Something Be Brewing in 3 Downtrodden Sectors?

Biotech, restaurants and retail have been left for dead but are showing signs of life today.

Regeneron Tries to Recover From Lows

Regeneron Tries to Recover From Lows

Prices pop today, but is this a reversal?

Regeneron May Cure the Market Blues

Regeneron May Cure the Market Blues

A potentially bullish pattern is setting up. 

How to Trade Regeneron's Pullback

How to Trade Regeneron's Pullback

Aggressive traders can go long REGN on the first up day.

Regeneron downgraded at Wells

Cramer: Here's Why Facebook's Stock Has Been Falling

Cramer: Here's Why Facebook's Stock Has Been Falling

Stocks like Facebook or Palo Alto Networks are expensive for the moment.

Cramer: See What Happens When Takeover Talk Gets Going?

Cramer: See What Happens When Takeover Talk Gets Going?

With Pfizer deal dead, Allergan is ready to go shopping.

Regeneron's Chart Has Degenerative Look

Regeneron's Chart Has Degenerative Look

The biopharmaceutical company's chart is still pointed lower. 

Jim Cramer Says Oracle Is Okay, But He Really Likes Salesforce.com

Jim Cramer Says Oracle Is Okay, But He Really Likes Salesforce.com

TheStreet’s Jim Cramer discussed the bear market in biotechs while answering viewer questions from social media on Friday.

Midday Report: Fox News Hits Record Profit; U.S. Stocks Waver

Midday Report: Fox News Hits Record Profit; U.S. Stocks Waver

U.S. stocks gave up earlier gains as the energy sector continued to sell off despite relatively stable crude prices on Tuesday.

Double Top Could Spell Double Trouble for Regeneron

Double Top Could Spell Double Trouble for Regeneron

The biopharmaceutical company is in for a deeper bear phase. 

Regeneron downgraded at Canaccord

Cramer: This Is Where I Say I Was Wrong

Cramer: This Is Where I Say I Was Wrong

My speculation on Fitbit and Alcoa didn't work out.

Jim Cramer Says Own Salesforce.com, Regeneron, First Solar

Jim Cramer Says Own Salesforce.com, Regeneron, First Solar

TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer says Macy's should benefit from the cold weather and energy stocks are still 'too dangerous' to put money into.

Have a CIGAR, You'll Go Far in 2016

Have a CIGAR, You'll Go Far in 2016

5 biotech stocks that could outperform the overall market in 2016.

Jim Cramer on Why Netflix, Chipotle and Regeneron Soared During QE

Jim Cramer on Why Netflix, Chipotle and Regeneron Soared During QE

TheStreet looked at stocks that soared under the Federal Reserve’s QE program, and Jim Cramer explains why some shares performed better than others.